Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
Phase 4
Completed
NCT04655170
| Condition | COPD Exacerbation |
|---|
| Phase | Phase 4 |
|---|
| Sponsor | University of Tennessee Graduate School of Medicine |
|---|
| Status | Completed |
|---|
| Enrollment | 60 participants |
|---|
| Interventions | Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) |
|---|
| Start date | Dec 9, 2020 |
|---|
| Completion date | Jan 19, 2023 |
|---|
| Results posted | Aug 3, 2026 |
|---|
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
Difference in Modified Borg Dyspnea Scale Scores Between Groups
From enrollment to the end of treatment at Day 7 · scores on a scale
| Experimental: Group 1: Revefenacin (YUPELRI) & Formoterol (Perforomist) | 1.89 scores on a scale |
|---|
| Active Comparator: Group 2: Ipratropium Bromide (Atrovent) & Albuterol(Ventolin) as Standard of Care | 1.92 scores on a scale |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.